The Effect of Femoral Nerve Block on Postoperative Opioid Use After Anterior Cruciate Ligament (ACL) Reconstruction
This trial is active, not recruiting.
|Treatment||administration of a femoral nerve block (bupivacaine hcl)|
|Sponsor||University of British Columbia|
|Start date||December 2010|
|End date||September 2011|
|Trial size||30 participants|
|Trial identifier||NCT00175630, H05-70078, W05-0024|
This study evaluates the effect of a femoral nerve block on opioid requirements following anterior cruciate ligament (ACL) reconstruction. This is a double blind, prospective randomized controlled trial.
|Endpoint classification||safety/efficacy study|
|Intervention model||parallel assignment|
|Masking||double blind (subject, investigator)|
Postoperative morphine requirement
time frame: Unspecified
time frame: immediately post-op
Opioid surgical time
time frame: time from end of anaesthesia to first requirement of morphine
Male or female participants from 12 years up to 17 years old.
Inclusion Criteria: - Schedule for primary elective anterior cruciate ligament reconstruction - Tolerance to bupivacaine - Tolerance to non-steroidal anti-inflammatory drugs (NSAIDs) - Informed consent Exclusion Criteria: - Patients who received a femoral nerve block more than 1 hour prior to surgery - Complex associated injuries or pre-existing conditions that will delay time to ambulation - Children with tibial avulsion fractures - Allergic and/or sensitive to bupivacaine and/or NSAIDs - 30% over ideal body weight - Acute ACL reconstruction (done less than 2 weeks after injury) - Pre-existing femoral nerve injury - Psychiatric patients on psychotropic agents - History of drug or alcohol dependence or recreational drug use - Refusal to provide informed consent
|Official title||Effect of Femoral Nerve Block on Opioid Requirements Following Anterior Cruciate Ligament Reconstruction: A Double Blind, Prospective Randomized Controlled Trial|
|Principal investigator||Christopher Reilly, MD|
Call for more information